隨著傳染病持續對人類健康構成重大威脅，且多重抗藥性菌株(Multidrug-Resistant Organisms, MDROs)快速演化，尤其引發的敗血症與由MDROs所引發之感染，都成為醫療臨床照護中高度關注的議題，因應此全球挑戰，世界衛生組織已呼籲各國推動即時檢測與抗生素管理相關策略。中國醫藥大學附設醫院（位於臺灣臺中）前瞻布局，率先開發導入智抗菌平台(Intelligent AntimicrobialSystem, i.A.M.S)，此平台具結合人工智慧(Artificial Intelligence, AI)與資訊科技創新，有涵蓋四大核心功能：敗血症與死亡風險預警系統、預測抗藥性菌株風險系統、個人抗菌譜，以及抗生素臨床決策輔助系統。以透過與電子病歷系統之整合，本平台能有效簡化臨床作業流程、提升診斷治療品質，同時強化抗生素使用之安全性與適切性。此外，視覺化介面設計，具備即時推送警示訊息，實現醫療資訊系統與AI間的即時連動，強化感染風險預測與智能化用藥決策。

As infectious diseases continue to pose severe threats to human health and multidrug-resistant organisms (MDROs) rapidly evolve, sepsis and infections caused by MDROs have become critical concerns in clinical care. In response, the World Health Organization has called for global action to develop real-time detection and antibiotic stewardship strategies. To address these challenges, China Medical University Hospital in Taichung, Taiwan, established an Intelligent Antimicrobial System (i.A.M.S.), an innovative platform that integrates artificial intelligence (AI) and information technology. The i.A.M.S. platform comprises four systems: a sepsis and mortality prediction system, a rapid MDRO prediction system, a personalized antibiogram system, and an antibiotic clinical decision support system. By integrating electronic medical records, the system streamlines clinical workflows, enhances treatment quality, and ensures the safety and appropriateness of antibiotic use. Additionally, the system issues alerts through an event-driven interface that enables real-time communication between healthcare information systems and AI.